Drug Trial Radar · NCT06842355
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Mar 4, 2025
Primary completion
Jan 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Tyra Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Conditions
- Achondroplasia
Interventions
TYRA-300 0.125 mg/kgDrug
Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.
TYRA-300 0.25 mg/kgDrug
Subsequent dose level escalations will occur based on criteria outlined in the protocol.
TYRA-300 0.375 mg/kgDrug
Subsequent dose level escalations will occur based on criteria outlined in the protocol.
TYRA-300 0.50 mg/kgDrug
Subsequent dose level escalations will occur based on criteria outlined in the protocol.
TYRA-300 0.625 mg/kgDrug
Subsequent dose level escalations may occur based on criteria outlined in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-related adverse events as assessed by CTCAE v5.0Time frame: Up to 12 months
- Change from baseline in annualized growth velocity (Cohort 1)Time frame: 12 months
Locations
26 sites in 8 countries. Site status is shown where the registry gives one.
Lundquist Institute for Biomedical Innovation
Torrance, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Nemours Alfred I duPont Hospital for Children
Wilmington, Delaware · Recruiting
Johns Hopkins University School of Medicine
Baltimore, Maryland · Recruiting
Uncommon Cures
Chevy Chase, Maryland · Recruiting
University of Missouri
Columbia, Missouri · Recruiting
Washington University
St Louis, Missouri · Recruiting
Duke University Hospital
Durham, North Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Children's Medical Center, Dallas
Dallas, Texas · Recruiting
University of Texas Health Science Center Medical School at Houston
Houston, Texas · Recruiting
University of Wisconsin-Madison
Madison, Wisconsin · Recruiting
The Children's Hospital at Westmead
Westmead, New South Wales, Australia · Recruiting
Royal Children's Hospital
Parkville, Victoria, Australia · Recruiting
Women's and Children's Health Research Institute, University of Alberta
Edmonton, Alberta, Canada · Recruiting
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada · Recruiting
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
Imagine Institute
Paris, France · Recruiting
CHU de Montpellier Parent
Montpellier, Herault, France · Recruiting
UMC Utrecht
Utrecht, Netherlands · Recruiting
Unidad de Cirugía Artroscópica (MIKS Hospital)
Vitoria-Gasteiz, Alava, Spain · Recruiting
Hospital Univeristario La Paz
Madrid, Madrid, Spain · Recruiting
Astrid Lindgren Children's Hospital (Karolinska University Hospital)
Stockholm, Sweden · Recruiting
Guy's & St Thomas NHS Foundation Trust 2
London, Greater London, United Kingdom · Recruiting
Great Ormond Street Hospital
London, Greater London, United Kingdom · Recruiting
Sheffield Children's Hospital
Sheffield, South Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.